ideasIdea

A formal regulatory route for validating a biomarker on archived trial samples

Completed trials have stored samples. Testing a new biomarker on them with the plan written in advance is nearly as good as a new trial and far cheaper, but regulators have no clear route to accept it.

The prospective-retrospective design (Simon, Paik and Hayes) uses archived samples from a completed randomised trial with a pre-specified analysis plan to validate a predictive biomarker. It rescued KRAS testing for anti-EGFR antibodies and Oncotype DX. Regulators accept it case by case. A published guidance with requirements (sample availability above a threshold, pre-registered analysis plan, independent statistical execution) would make the route predictable and encourage sponsors to bank and share samples.

Hypothesis

Guidance will double the number of biomarker label changes supported by prospective-retrospective analyses within five years and cut the average time from biomarker hypothesis to label from six years to three.

Rationale

The design is accepted in the methodological literature and has produced several practice changes; the barrier is regulatory uncertainty and sample access.

What would test it

Draft and publish guidance; track submissions and outcomes; compare with the preceding five years.

Maturity

early clinical

Who has to act

regulator

Cost to try

Small (under $1M)

Years to first evidence

Bottlenecks it attacks

Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.

Connected

7top

Pages like this

not linked directly; found by shared links

A formal regulatory route for validating a biomarker on archived trial samples

Connected

Pages like this

drugs

terms

trials

ideas

bottlenecks